UNSPSC 51202804: Tacrolimus

This classification denotes a mtor inhibitor and immunosuppressant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) WM0HAQ4WNM. European Medicines Agency schedules Tacrolimus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10797MIG. Tacrolimus generally arises in the molecular formula C44H69NO12.

UNSPSC 51202804 Tacrolimus is a Commodity code that covers pharmaceutical procurement, but the recent state and local opportunities tagged under this code reflect a broader pattern of public-health pharmaceutical purchasing that does not align with tacrolimus specifically. State and local governments use this code tier to procure a wide range of pharmaceutical products through competitive bidding and cooperative purchasing vehicles. The issuing bodies include state health departments and county public-health authorities, which leverage both direct solicitations and piggyback agreements with multi-agency cooperative purchasing consortiums to acquire pharmaceuticals at scale. Procurement vehicles such as MMCAP Infuse and similar cooperative frameworks allow multiple jurisdictions to benefit from competitively awarded contracts, reducing administrative overhead and consolidating purchasing power.

Recent activity shows the Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026, for a total of $2.99 million over the initial term plus renewal options, though the award covered Doxycycline Hyclate and Ciprofloxacin Hydrochloride rather than tacrolimus. In Florida, Seminole County issued an IFB (Solicitation Number IFB60459723LAS) on June 30, 2026, to procure 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford and a response deadline of July 26, 2023. Recent activity concentrates in the Southeast and Midwest, with Illinois and Florida representing active jurisdictions. The code shows limited direct tacrolimus-specific solicitation in recent records; opportunities reflect state health departments and county authorities buying pharmaceuticals through cooperative contracts and competitive sealed bids rather than tacrolimus as a standalone product line.